

**Remarks**


Applicants have amended the Specification and the Claims.

The Specification has been amended to include a priority statement.

The claims follow the numbering as those filed as part of the PCT application to which this case claims priority. Claims 2-6 and 10-13 have been canceled. Claims 7-9, 14, 16 and 17 have been amended to remove dependency to the canceled claims. The Applicants assert that no new matter has been added by this amended.

No fee is deemed necessary in connection with the filing of this Amendment. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 502624

Respectfully submitted,



MaryAnn Wiskerchen  
Attorney for Applicants  
Registration No. 45,511  
Phone: 317-655-9326

Eli Lilly and Company  
Patent Division/MAW  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

Sept 21, 2006